-
Product Insights
Cutaneous Squamous Cell Carcinoma (cSCC) - Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Cutaneous Squamous Cell Carcinoma (cSCC) - Global Clinical Trials Review, 2025" provides an overview of Cutaneous Squamous Cell Carcinoma (cSCC) Clinical trials scenario. This report provides top line data relating to the clinical trials on Cutaneous Squamous Cell Carcinoma (cSCC). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Basal Cell Carcinoma (Basal Cell Epithelioma): Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Basal Cell Carcinoma (Basal Cell Epithelioma) - Global Clinical Trials Review, 2025" provides an overview of Basal Cell Carcinoma (Basal Cell Epithelioma) Clinical trials scenario. This report provides top line data relating to the clinical trials on Basal Cell Carcinoma (Basal Cell Epithelioma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase,...
-
Product Insights
Rhabdomyosarcoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Rhabdomyosarcoma - Global Clinical Trials Review, 2025" provides an overview of Rhabdomyosarcoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Rhabdomyosarcoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)- Global Clinical Trials Review, 2025" provides an overview of Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) Clinical trials scenario. This report provides top line data relating to the clinical trials on Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). Report includes an overview of trial numbers and their average enrollment in top countries conducted across...
-
Product Insights
High-Grade Glioma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “High-Grade Glioma- Global Clinical Trials Review, 2025" provides an overview of High-Grade Glioma Clinical trials scenario. This report provides top line data relating to the clinical trials on High-Grade Glioma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Sector Analysis
Pancreatic Cancer in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
This report covers the 8MM (US, France, Germany, Italy, Spain, UK, China, and Japan) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Pancreatic cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases. Key Highlights - Report deliverables include an Excel-based forecast model - Forecasts...
-
Sector Analysis
HER2-Negative Breast Cancer Epidemiology Analysis and Forecast to 2034
Breast cancer is a malignant tumor originating within the breast tissue. The most common type of breast cancer is invasive breast cancer, which originates from the milk ducts and invades the surrounding breast tissue (Cancer Research UK, 2023a). As it progresses, the cancer can metastasize to other parts of the body via the bloodstream and lymphatic system (American Cancer Society, 2022). According to the World Health Organization (WHO), breast cancer was the most common diagnosed cancer in women in 157...
-
Product Insights
Mycosis Fungoides Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Mycosis Fungoides - Global Clinical Trials Review, 2025" provides an overview of Mycosis Fungoides Clinical trials scenario. This report provides top line data relating to the clinical trials on Mycosis Fungoides. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Head and Neck Squamous Cell Carcinoma Epidemiology Analysis and Forecast to 2034
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group consisting of cancers of the mouth, including the lip, tongue, gum, floor of mouth, palate, and other parts of mouth (International Statistical Classification of Diseases and Related Health Problems 10th Revision [ICD-10] code = C00–C06); the salivary glands (ICD-10 code = C07–C08); the pharynx, including the tonsil, oropharynx, nasopharynx, pyriform fossa, hypopharynx, other mouth/pharynx (ICD-10 code = C09–C14); the nose, sinuses, and related structures (ICD-10 code = C30–C31), and...
-
Sector Analysis
Current Trends in Targeted Therapies in Non-Small Cell Lung Cancer (NSCLC) – Market Drivers and Challenges
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases There are currently ten actionable genomic alterations (AGAs) that are addressed by targeted therapy agents across multiple lines of therapy. Patients who did not undergo genetic testing or tested negative for AGAs, receive immunotherapy agents depending on their PD-L1 status. Chemotherapy works as salvage therapy for late-line recurrent/relapsed patients. - Targeted therapy in NSCLC is a highly competitive...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.